Highly Sensitive and Interference-Free Detection of Multiple Drug Molecules in Serum Using Dual-Modified SERS Substrates Combined with AI Algorithm Analysis.

Journal: Analytical chemistry
PMID:

Abstract

Surface-enhanced Raman spectroscopy (SERS) technology has shown broad potential in drug concentration detection, but its application in blood drug monitoring faces significant challenges. The primary difficulty lies in overcoming the interference caused by various biomolecules present in serum, which can severely obscure the SERS signals of target drug molecules. Traditional enhancement substrates are often limited to detecting single drugs and are prone to interference, making the label-free detection of multiple drugs particularly challenging. To address these issues, we developed a novel SERS substrate based on Au@AgNRs, which undergoes a two-step modification to produce Au@AgDBCNRs. This innovative substrate provides exceptional signal amplification, simultaneously allowing the sensitive detection of multiple drug molecules. Moreover, our method eliminates the need for serum deproteinization, enabling the direct detection of drugs in serum while effectively mitigating interference from blood components. The cetyltrimethylammonium bromide coating on Au@AgDBCNRs is an internal standard for drug quantification without additional standards. The platform significantly improves detection accuracy and efficiency by automatically integrating artificial intelligence to recognize and analyze Raman spectral features. This novel SERS platform provides a new idea for therapeutic drug monitoring and is expected to provide rapid, accurate, and cost-effective drug detection in the clinical environment, which has great potential in improving patient care and optimizing drug dosage strategies.

Authors

  • Yingji Wang
    State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Research Center for Innovative Technology of Pharmaceutical Analysis, College of Pharmacy, Harbin Medical University, Heilongjiang, 150081, PR China.
  • Jin Sun
    Department of Biopharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road, Shenyang 110016, China.
  • Liping Zhou
    DigiM Solution LLC, Burlington, MA 01803, USA.
  • Guangrun Wu
    State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Research Center for Innovative Technology of Pharmaceutical Analysis, College of Pharmacy, Harbin Medical University, Heilongjiang, 150081, P. R. China.
  • Siqi Gong
    State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Research Center for Innovative Technology of Pharmaceutical Analysis, College of Pharmacy, Harbin Medical University, Heilongjiang, 150081, PR China.
  • Zibo Gao
    State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Research Center for Innovative Technology of Pharmaceutical Analysis, College of Pharmacy, Harbin Medical University, Heilongjiang, 150081, PR China.
  • Jing Wu
    School of Pharmaceutical Science, Jiangnan University, Wuxi, 214122, Jiangsu, China.
  • Chaochao Ma
    State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Research Center for Innovative Technology of Pharmaceutical Analysis, College of Pharmacy, Harbin Medical University, Harbin 150081, China.
  • Yun Zou
    Washington University in St. Louis, Department of Biomedical Engineering, St. Louis, Missouri, United States.
  • Xiaoyu Liu
    State Grid Hebei Electric Power Co., Ltd., Marketing Service Center, Shijiazhuang 050035, China.
  • Rongheng Ma
    The Fourth Affiliated Hospital of Harbin Medical University, Harbin Medical University, Heilongjiang 150081, PR China.
  • Xin Zhang
    First Department of Infectious Diseases, The First Affiliated Hospital of China Medical University, Shenyang, China.
  • Zhaoying Zhang
    The Fourth Affiliated Hospital of Harbin Medical University, Harbin Medical University, Heilongjiang 150081, PR China.
  • Yang Li
    Occupation of Chinese Center for Disease Control and Prevention, Beijing, China.